Adaptive Biotechnologies (NASDAQ: ADPT) director sells at $26, keeps 78,639

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp (ADPT) director Katey Einterz Owen reported a sale of company stock. On 2026-08-26, Owen sold 9,615 shares of Common Stock in a sale in open market or private transaction at $26.00 per share, and reported owning 78,639 shares of Common Stock directly after the transaction.

Insider Trade Summary

Net Seller: 9,615 shares

Net Sell 1 txn

Insider OWEN KATEY EINTERZ

Role Director

Sold 9,615 shs ($250K)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,615	$26.00	$250K

Holdings After Transaction: Common Stock — 78,639 shares (Direct)

Key Figures

Shares sold: 9,615 shares of Common Stock Sale price per share: $26.00 per share Shares owned after transaction: 78,639 shares of Common Stock +1 more

4 metrics

Shares sold 9,615 shares of Common Stock Sale on 2026-08-26 by director Katey Einterz Owen

Sale price per share $26.00 per share Price for the 9,615-share sale on 2026-08-26

Shares owned after transaction 78,639 shares of Common Stock Direct ownership reported following the sale

Net shares sold in filing 9,615 shares transactionSummary netBuySellShares for this Form 4

Key Terms

Common Stock, transaction code, sale in open market or private transaction

3 terms

Common Stock financial

"security_title: "Common Stock" for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

transaction code financial

"transaction_code: "S" indicating a sale transaction"

sale in open market or private transaction financial

"transaction_code_description: "Sale in open market or private transaction""

FAQ

What insider transaction did ADPT director Katey Einterz Owen report?

Katey Einterz Owen reported a sale of 9,615 shares of Adaptive Biotechnologies Corp Common Stock on 2026-08-26 in a sale categorized as an open market or private transaction at $26.00 per share.

How many ADPT shares did Katey Einterz Owen sell and at what price?

Katey Einterz Owen sold 9,615 shares of Adaptive Biotechnologies Corp Common Stock at a reported price of $26.00 per share on 2026-08-26.

What is Katey Einterz Owen’s ADPT share ownership after this Form 4 transaction?

After the reported transaction, Katey Einterz Owen directly owns 78,639 shares of Adaptive Biotechnologies Corp Common Stock, as stated in the Form 4 data.

Was the ADPT insider transaction a purchase or a sale?

The transaction reported by Katey Einterz Owen was a sale of Common Stock, coded as transaction code S, indicating a sale in an open market or private transaction.

Did the ADPT Form 4 indicate any derivative security exercises?

No. The Form 4 data show no derivative transactions; the single reported transaction involves Common Stock only, with derivativeTransactionCount listed as 0.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/28/2026 - 05:50 PM Accepted by SEC EDGAR 08/28/2026 - 05:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OWEN KATEY EINTERZ

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE WASHINGTON 98109

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/26/2026		S		9,615	D	$26	78,639	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Katey Einterz Owen by Clarice McCauley, Attorney-in-Fact	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)